bacterial ribosomal proteins Inhibitors
2 drugsAbout bacterial ribosomal proteins
Bacterial ribosomal proteins are essential components of the bacterial ribosome, responsible for protein synthesis. Disrupting ribosome function halts bacterial growth, making these proteins attractive antibacterial targets.
While there is no genetic evidence directly linking bacterial ribosomal proteins to human diseases, their importance in bacterial survival is well-established, supporting their therapeutic relevance.
Bacterial ribosomal proteins are targeted by two FDA-approved small molecule drugs: MACRODANTIN (first approved in 1970) and MACROBID. Both drugs are marketed by ALMATICA for bacterial infection indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Uncomplicated Urinary Tract Infections with only 1 trials.
Top bacterial ribosomal proteins Drugs
The competitive landscape is highly concentrated, with ALMATICA being the only company with approved drugs.
High market concentration suggests potential entry barriers; focus on novel mechanisms or indications.
bacterial ribosomal proteins Drug Modality Landscape
Modalities
Routes of Administration
bacterial ribosomal proteins is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like peptides or oligonucleotides to differentiate from existing therapies.
bacterial ribosomal proteins Clinical Trials 33 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 1 | 0 | 1 | 100% |
| Phase 2 | 1 | 1 | 0 | 0 | 100% |
| Phase 3 | 6 | 3 | 1 | 2 | 75% |
| Phase 4 | 23 | 13 | 2 | 8 | 87% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
bacterial ribosomal proteins Drug Approval Timeline (1970 - 1991)
The approval timeline spans 22 years, with the first drug approved in 1970 and the most recent in 1991.
The long gap since the last approval suggests potential saturation; consider targets with more recent activity.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 38 clinical trials targeting bacterial ribosomal proteins.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities